Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 22 - Sayı: 3

Rare presentation and wide intrafamilial variability of Fabry disease: A case report and review of the literature

Pages
154–158
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene, which encodes α-galactosidase A, leading to an intralysosomal accumulation of globotriaosilceramide (Gb3) in a wide variety of cells.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene, which encodes α-galactosidase A, leading to an intralysosomal accumulation of globotriaosilceramide (Gb3) in a wide variety of cells.
📊
Key Findings & Data:Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene, which encodes α-galactosidase A, leading to an intralysosomal accumulation of globotriaosilceramide (Gb3) in a wide variety of cells.
💡
Conclusion & Impact:Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene, which encodes α-galactosidase A, leading to an intralysosomal accumulation of globotriaosilceramide (Gb3) in a wide variety of cells.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene, which encodes α-galactosidase A, leading to an intralysosomal accumulation of globotriaosilceramide (Gb3) in a wide variety of cells.

🔖

Cite This Article

MILITARU, S., ADAM, R., DOROBANTU, L., FERRAZZI, P., LASCONE, M., RADOİ, V., GENER, İ., POPESCU, B. A., JURCUT, R. (2019). Rare presentation and wide intrafamilial variability of Fabry disease: A case report and review of the literature. The Anatolian Journal of Cardiology, Cilt: 22 - Sayı: 3, 154–158. https://ajindex.com/articles/366800

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mehta A, Widmer U. Natural history of Fabry disease. Fabry Disease: Perspectives from 5 Years of FOS. Mehta A, Beck M, SunderPlassmann G, editors. Oxford: Oxford PharmaGenesis; 2006
  2. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010; 5: 2220-8
  3. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, et al. Onset and progression of the Anderson–Fabry disease related cardiomyopathy. Int J Cardiol 2008; 130: 367-73
  4. Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Heliö T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 1448-58
  5. Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C, et al. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol 2015; 66: 1687-96
  6. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93: 528-35
  7. Militaru S, Ginghină C, Popescu BA, Săftoiu A, Linhart A, Jurcuţ R. Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets. Eur Heart J Cardiovasc Imaging 2018; 19: 1313-22
  8. Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol 2011; 37: 37-43
  9. Krämer J, Niemann M, Liu D, Hu K, Machann W, Beer M, et al. Twodimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 2013; 34: 1587-96
  10. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, Aschauer S, Duca F, Bachmann A, et al. T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication. JACC Cardiovasc Imaging 2016; 9: 14-23
  11. Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holzmeister J, Lüscher TF, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart 2011; 97: 485-90
  12. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol